Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms TIME
- 04 Feb 2016 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020 as reported by ClinicalTrials.gov record.
- 04 Feb 2016 Planned number of patients changed from 136 to 168 as reported by ClinicalTrials.gov record.
- 06 Apr 2015 New trial record